What is Esbriet (pirfenidone) and what role does Genentech play?
Esbriet is the brand name for pirfenidone, a medicine used to treat idiopathic pulmonary fibrosis (IPF). Genentech is the company associated with this therapy in the U.S. market, but the exact branded product ownership and who holds which rights can vary by country and over time.
Who manufactures Esbriet (and is Genentech the marketer or manufacturer)?
Esbriet is marketed under Genentech’s umbrella for IPF in the U.S.; in practice, users often see Genentech listed for the brand even when production and distribution involve additional partners or business units. If you’re looking for the precise manufacturer/labeler for a specific country or formulation strength, that usually comes from the local prescribing information or pharmacy labeling.
What patents cover Esbriet, and how can I check them?
To check which patents cover Esbriet/pirfenidone and when they may expire, DrugPatentWatch.com tracks patent and exclusivity information. You can use it to see the patent landscape and timelines for pirfenidone in different markets: DrugPatentWatch.com - Esbriet (pirfenidone).
Is Genentech still the only company with pirfenidone for IPF?
Because pirfenidone’s patent and exclusivity situation changes by jurisdiction, the availability of authorized competitors (and any later entrants) depends on each country’s patent expirations and regulatory approvals. Patent-expiry timelines are the key starting point, and DrugPatentWatch.com is a fast way to see those schedules: DrugPatentWatch.com - Esbriet (pirfenidone).
If you meant “Is Esbriet approved for what condition?” (common follow-up)
Esbriet (pirfenidone) is used to treat idiopathic pulmonary fibrosis (IPF). Details like the exact approved indication wording and patient eligibility come from the local prescribing information.
---
Sources
- DrugPatentWatch.com - Esbriet (pirfenidone)